Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2015, Vol. 9 Issue (3) : 368-373     DOI: 10.1007/s11684-015-0403-1
Glucagon-like peptide-2 exhibits protective effect on hepatic ischemia-reperfusion injury in rats
Naci Topaloğlu1,Adem Küçük2,Şule Yıldırım1,*(),Mustafa Tekin1,Havva Erdem3,Mustafa Deniz4
1. ?anakkale Onsekiz Mart University Medical Faculty, Department of Pediatrics, ?anakkale, Turkey
2. Düzce Atatürk State Hospital, Department of Pediatric Surgery, Düzce, Turkey
3. Düzce University Medical Faculty, Department of Pathology, Düzce, Turkey
4. ?anakkale Onsekiz Mart University Medical Faculty, Department of Physiology, ?anakkale, Turkey
Download: PDF(356 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Glucagon-like peptide-2 (GLP-2) has potent anti-inflammatory effects and protects against experimental ischemia/reperfusion (I/R) injury in pulmonary, intestinal, and myocardial tissue. However, its protective abilities against I/R injury in the liver are unknown. We investigated the potential role of GLP-2 pretreatment on hepatic I/R injury in rats. A total of 24 rats were randomly divided into three groups (n = 8). The first group was the control group; the second group was the vehicle-treated hepatic ischemia/reperfusion (HIR, vehicle saline-treated) group; and the third group was the GLP-2 pretreated I/R (GLP2-IR) group. Each rat in the third group was intraperitoneally administered 5 μg GLP-2 for 5 d before the procedure. A portal triad was created to induce ischemia with a vascular atraumatic clamp. After 40 min, the clamp was released to initiate hepatic reperfusion for 6 h. Blood samples and tissue specimens from the liver were obtained. Alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels significantly increased in the saline-treated HIR group (P<0.001), whereas GLP-2 pretreatment significantly decreased their levels (P<0.01). Our data suggested that GLP-2 pretreatment may have a protective effect on liver I/R injury. However, dose-response studies are necessary to determine the most effective dose.

Keywords ischemia/reperfusion      liver      glucagon-like peptide-2      alanine aminotransferase     
Corresponding Authors: ?ule Y?ld?r?m   
Just Accepted Date: 07 July 2015   Online First Date: 21 August 2015    Issue Date: 26 August 2015
URL:     OR
Control (mean±SEM) HIR (mean±SEM) GLP2-IR (mean±SEM)
AST (n = 8) (U/L) 102.50±10.29 435.71±26.00 223.87±58.00
ALT (n = 8) (U/L) 34.75±3.57 365.71±55.00 164.14±65.00
Total bilirubin (n = 8) (mg/dl) 0.06±0.08 0.12±0.01 0.05±0.00
Total protein (n = 8) (g/dl) 5.08±0.13 5.37±0.09 5.37±0.17
GGT (n = 8) (U/L) 0.12±0.12 1.37±0.32 0.62±0.183
ALP (n = 8) (U/L) 74.11±13.00 134.62±9.56 128.87±7.13
Tab.1  Serum levels of AST, ALT, total bilirubin, total protein, GGT and ALP of rats in the groups
Fig.1  Histopathological liver specimens from rats. (A) Control group: normal liver tissue. (B) Specimens of HIR group. Liver specimens after ischemia reperfusion exhibited focal necrosis and infiltration of leukocytes. (C) Specimens of GLP2-IR group. GLP-2 treatment did not significantly decrease these pathological changes (P?>?0.05).
Fig.2  The effect of saline, I/R, and GLP-2 pretreatment on microscopic damage scores. *P?<?0.05; compared with the control group.
1 Abu-Amara M, Yang SY, Tapuria N, Fuller B, Davidson B, Seifalian A. Liver ischemia/reperfusion injury: processes in inflammatory networks—a review. Liver Transpl 2010; 16(9): 1016–1032
doi: 10.1002/lt.22117 pmid: 20818739
2 Taki-Eldin A, Zhou L, Xie HY, Chen KJ, Yu D, He Y, Zheng SS. Triiodothyronine attenuates hepatic ischemia/reperfusion injury in a partial hepatectomy model through inhibition of proinflammatory cytokines, transcription factors, and adhesion molecules. J Surg Res 2012; 178(2): 646–656
doi: 10.1016/j.jss.2012.05.069 pmid: 22727940
3 Rushing GD, Britt LD. Reperfusion injury after hemorrhage: a collective review. Ann Surg 2008; 247(6): 929–937
doi: 10.1097/SLA.0b013e31816757f7 pmid: 18520219
4 Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 2007; 46(14): 1063–1070
doi: 10.2169/internalmedicine.46.0059 pmid: 17634701
5 Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury—a review. J Surg Res 2008; 150(2): 304–330
doi: 10.1016/j.jss.2007.12.747 pmid: 19040966
6 Kandilci HB, Gümü?el B. Ischemia-reperfusion injury and ischemic preconditioning in lungs. Hacettepe University Journal of the Faculty of Pharmacy 2005; 25: 35–49 (in Turkish)
7 Kaplowitz N. Mechanisms of liver cell injury. J Hepatol 2000; 32(1 Suppl): 39–47
doi: 10.1016/S0168-8278(00)80414-6 pmid: 10728793
8 Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 284(1): G15–G26
doi: 10.1152/ajpgi.00342.2002 pmid: 12488232
9 Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003; 18(8): 891–902
doi: 10.1046/j.1440-1746.2003.03056.x pmid: 12859717
10 Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Nichols BL, Burrin DG. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130(1): 150–164
doi: 10.1053/j.gastro.2005.11.005 pmid: 16401478
11 Bremholm L, Hornum M, Henriksen BM, Larsen S, Holst JJ. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009; 44(3): 314–319
doi: 10.1080/00365520802538195 pmid: 19005872
12 Bremholm L, Hornum M, Andersen UB, Hartmann B, Holst JJ, Jeppesen PB. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept 2011; 168(1-3): 32–38
doi: 10.1016/j.regpep.2011.03.003 pmid: 21421014
13 Deniz M, Bozkurt A, Kurtel H. Mediators of glucagon-like peptide 2-induced blood flow: responses in different vascular sites. Regul Pept 2007; 142(1-2): 7–15
doi: 10.1016/j.regpep.2007.01.002 pmid: 17346812
14 Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000; 47(1): 112–119
doi: 10.1136/gut.47.1.112 pmid: 10861272
15 Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58(8): 1091–1103
doi: 10.1136/gut.2008.165886 pmid: 19240062
16 Ivory CP, Wallace LE, McCafferty DM, Sigalet DL. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2008; 295(6): G1202–G1210
doi: 10.1152/ajpgi.90494.2008 pmid: 18845573
17 Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007; 293(1): G211–G221
doi: 10.1152/ajpgi.00530.2006 pmid: 17395898
18 Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999; 96(4): 1569–1573
doi: 10.1073/pnas.96.4.1569 pmid: 9990065
19 Thulesen J, Hartmann B, ?rskov C, Jeppesen PB, Holst JJ, Poulsen SS. Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected (125)I-GLP-2. Peptides 2000; 21(10): 1511–1517
doi: 10.1016/S0196-9781(00)00305-3 pmid: 11068098
20 Chiappa AC, Makuuchi M, Zbar AP, Biella F, Vezzoni A, Torzilli G, Andreoni B. Protective effect of methylprednisolone and of intermittent hepatic pedicle clamping during liver vascular inflow occlusion in the rat. Hepatogastroenterology 2004; 51(59): 1439–1444
pmid: 15362771
21 Aslan A, Karagüzel G, Celik M, Uysal N, Yücel G, Melikoglu M. Pentoxifylline contributes to the hepatic cytoprotective process in rats undergoing hepatic ischemia and reperfusion injury. Eur Surg Res 2001; 33(4): 285–290
doi: 10.1159/000049719 pmid: 11684835
22 Portakal O, Inal-Erden M. Effects of pentoxifylline and coenzyme Q10 in hepatic ischemia/reperfusion injury. Clin Biochem 1999; 32(6): 461–466
doi: 10.1016/S0009-9120(99)00041-7 pmid: 10667482
23 Vardareli E, Sar?cam T, Koken T, Degirmenci I, Aral E, Erenoglu E. The effect of alpha-tocopherol and pentoxyfilline on ischemia-reperfusion induced liver injury in rats. Hepatogastroenterology 1998; 45(23): 1505–1508
pmid: 9840094
24 Y?ld?r?m S, Tok H, K?ksal H, Erdem L, Baykan A. Allopurinol plus pentoxifilline in hepatic ischaemia/reperfusion injury. Asian J Surg 2002; 25(2): 149–153
doi: 10.1016/S1015-9584(09)60164-0 pmid: 12376236
25 Vaghasiya JD, Sheth NR, Bhalodia YS, Jivani NP. Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide. Saudi J Gastroenterol 2010; 16(3): 174–180
doi: 10.4103/1319-3767.65187 pmid: 20616412
26 Ozturk H, Gezici A, Ozturk H. The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats. Hepatol Res 2006; 34(2): 76–83
doi: 10.1016/j.hepres.2005.11.003 pmid: 16384742
27 Farber JL, Gerson RJ. Mechanism of cell injury with hepatotoxic chemicals. Pharmacol Rew 1984; 36: 715–745
28 Hearse DJ. Reperfusion of the ischemic myocardium. J Mol Cell Cardiol 1977; 9(8): 605–616
doi: 10.1016/S0022-2828(77)80357-X pmid: 903971
29 Arda-Pirincci P, Bolkent S. The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D. Mol Cell Biochem 2011; 350(1-2): 13–27
doi: 10.1007/s11010-010-0678-0 pmid: 21153865
30 Neuman MG. Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci 2001; 38(2): 109–166
doi: 10.1080/20014091084182 pmid: 11347718
31 Rüdiger HA, Graf R, Clavien PA. Liver ischemia: apoptosis as a central mechanism of injury. J Invest Surg 2003; 16(3): 149–159
doi: 10.1080/08941930390205764 pmid: 12775431
32 Schmeling DJ, Caty MG, Oldham KT, Guice KS. Cytoprotection by diclofenac sodium after intestinal ischemia/reperfusion injury. J Pediatr Surg 1994; 29(8): 1044–1048
doi: 10.1016/0022-3468(94)90276-3 pmid: 7965503
33 Tsung A, Kaizu T, Nakao A, Shao L, Bucher B, Fink MP, Murase N, Geller DA. Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation 2005; 79(2): 196–204
doi: 10.1097/01.TP.0000151681.07474.2E pmid: 15665768
34 Schmeding M, Neumann UP, Boas-Knoop S, Spinelli A, Neuhaus P. Erythropoietin reduces ischemia-reperfusion injury in the rat liver. Eur Surg Res 2007; 39(3): 189–197
doi: 10.1159/000101009 pmid: 17377393
35 Erdo?an O, Y?ld?z S, Ba?aran A, Demirba? A, Ye?ilkaya A. Effect of intraportal verapamil infusion on hepatic ischemia-reperfusion injury. Pol J Pharmacol 2001; 53(2): 137–141
pmid: 11787953
36 Hiranuma S, Ito K, Noda Y, Ozasa H, Koike Y, Horikawa S. Amelioration of hepatic ischemia/reperfusion injury in the remnant liver after partial hepatectomy in rats. J Gastroenterol Hepatol 2007; 22(12): 2167–2172
doi: 10.1111/j.1440-1746.2006.04779.x pmid: 18031376
37 Taylor-Edwards CC, Burrin DG, Kristensen NB, Holst JJ, McLeod KR, Harmon DL. Glucagon-like peptide-2 (GLP-2) increases net amino acid utilization by the portal-drained viscera of ruminating calves. Animal 2012; 6(12): 1985–1997
doi: 10.1017/S175173111200095X pmid: 23031436
38 Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, Burrin DG. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 2003; 125(1): 136–147
doi: 10.1016/S0016-5085(03)00667-X pmid: 12851879
[1] Jing Zhang,Shan Gao,Zhongping Duan,Ke-Qin Hu. Overview on acute-on-chronic liver failure[J]. Front. Med., 2016, 10(1): 1-17.
[2] Jiabo Wang,Zhijie Ma,Ming Niu,Yun Zhu,Qingsheng Liang,Yanling Zhao,Jingyuan Song,Zhaofang Bai,Yaming Zhang,Ping Zhang,Na Li,Yakun Meng,Qi Li,Lushan Qin,Guangju Teng,Junling Cao,Baosen Li,Shilin Chen,Yonggang Li,Zhengsheng Zou,Honghao Zhou,Xiaohe Xiao. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum[J]. Front. Med., 2015, 9(4): 457-467.
[3] Lixia Gan,Wei Xiang,Bin Xie,Liqing Yu. Molecular mechanisms of fatty liver in obesity[J]. Front. Med., 2015, 9(3): 275-287.
[4] Daniel Wai-Hung Ho,Alan Ka-Lun Kai,Irene Oi-Lin Ng. TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma[J]. Front. Med., 2015, 9(3): 322-330.
[5] Zhuping Cao,Shiqi Liu,Jianhua Niu,Bing Wei,Jie Xu. Severe hepatoxicity caused by aspirin overdose: a case report[J]. Front. Med., 2015, 9(3): 388-391.
[6] Farhad Sahebjam,John M. Vierling. Autoimmune hepatitis[J]. Front. Med., 2015, 9(2): 187-219.
[7] Yi Liang,Qisheng Feng,Jian Hong,Futuo Feng,Yi Sang,Wenrong Hu,Miao Xu,Roujun Peng,Tiebang Kang,Jinxin Bei,Yixin Zeng. Tumor growth and metastasis can be inhibited by maintaining genomic stability in cancer cells[J]. Front. Med., 2015, 9(1): 57-62.
[8] Ru Zhang,Qiang Wang,Lin Zhang,Saijuan Chen. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B[J]. Front. Med., 2015, 9(1): 90-99.
[9] Lei Li,Yimei Liu,Tiancheng Luo,Jian Zhou,Yingyong Hou,Xizhong Shen,Jiyao Wang. Comprehensive treatment of acute-on-chronic liver failure in a patient with hepatitis B: a case report[J]. Front. Med., 2014, 8(2): 250-253.
[10] Sandy Leung-Kuen Au, Irene Oi-Lin Ng, Chun-Ming Wong. Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins[J]. Front Med, 2013, 7(2): 231-241.
[11] Cong Tong, Xinsen Xu, Chang Liu, Tianzheng Zhang, Kai Qu. Assessment of liver volume variation to evaluate liver function[J]. Front Med, 2012, 6(4): 421-427.
[12] Hongchi Jiang, Jizhou Wang. Emergency strategies and trends in the management of liver trauma[J]. Front Med, 2012, 6(3): 225-233.
[13] Kai Qu, Chang Liu, Aasef M A Mansoor, Bo Wang, Jincai Chen, Liang Yu, Yi Lv. Pyogenic liver abscess as initial presentation in locally advanced right colon cancer invading the liver, gallbladder, and duodenum[J]. Front Med, 2011, 5(4): 434-437.
[14] Jia Wei, Jiexiong Feng. Laparoscopic treatment of liver diseases in children[J]. Front Med, 2011, 5(4): 388-394.
[15] Hui Dong, Fu’er Lu, Nan Wang, Xin Zou, Jingjing Rao. Type 2 diabetic patients with non-alcoholic fatty liver disease exhibit significant haemorheological abnormalities[J]. Front Med, 2011, 5(3): 288-293.
Full text